Sergei I. Kuznetsov

Sergei I. Kuznetsov

Auto-generated profile, based on publicly available information

Sergei I. Kuznetsov

Samara State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Science and Innovations in Medicine
Verified
Journal Article
Open access
PDF file
LVLarisa Volova
Larisa Volova
NONatalya Ossina
Natalya Ossina
SKSergei I. Kuznetsov
Sergei I. Kuznetsov
OGOksana A. Gusyakova
Oksana A. Gusyakova
Denis G. AlekseevDenis G. Alekseev
Denis G. Alekseev
КИКузнецов Сергей Иванович
Кузнецов Сергей Иванович
Aim – to study the immunomodulator-induced individual cytokine production by peripheral blood mononuclear cells (PBMCs) and to evaluate the potential of using this approach as a universal cellular test system in personalized medicine. Material and methods. The peripheral blood mononuclear cells given by donors were cultured in vitro in the presence of immunomodulators Imunofan and Polyoxidonium. After incubation, the enzyme-linked immunosorbent assay (ELISA) of the culture medium for the presence of pro-inflammatory cytokines IL-6, IL-8/CXCL8, MCP-1/CCL2, and IFN-α cytokines was performed. Results. The results of the experiment have demonstrated the absence of spontaneous or immunomodulator-induced production of IFN-α by PBMCs. These data correspond to the information presented earlier in the scientific literature. We also observed a pronounced inhibitory effect of both immunomodulators on the production of cytokines MCP-1/CCL2, IL-6, IL-8/CXCL8 by PBMCs, along with the individual variability of their production and the cumulative effect of production over time. Conclusion. The features of the production of pro-inflammatory cytokines by PBMCs into the medium in the presence of immunomodulators, revealed by the in vitro screening, can be used to develop universal in vitro cellular test systems for personalized diagnosis of a number of socially significant inflammatory and autoimmune diseases.

6 May 2024 in Science and Innovations in Medicine
Verified
Journal Article
Open access
LVLarisa Volova
Larisa Volova
EPEvgeniy Pugachev
Evgeniy Pugachev
TSTatyana V. Starikova
Tatyana V. Starikova
PLPetr Lebedev
Petr Lebedev
ISIrina А. Shafieva
Irina А. Shafieva
КСКузнецов Сергей
Кузнецов Сергей
Aim– to develop anin vitromethod for assessing the activity of the inflammasome under conditions of hyperuricemic stimulation of inflammatory interleukins. Material and methods.Whole blood cells of donors and patients with hyperuricemia and exacerbation of gouty arthritis diluted with RPMI were culturedin vitroin the presence of different concentrations of uric acid. The production of cytokines in the cell growth media of hematopoietic cells stimulated with uric acid was evaluated using an enzyme-linked immunosorbent assay (ELISA). Results.By simulating the hyperuricemiain vivo, anin vitrocell-based bioassay was developed to stimulate blood cells of individual donors with uric acid. Using the developedin vitroHyperuricemia-hemotest bioassay, quantitative differences were found in the production of inflammatory cytokines by the blood cells of potentially healthy donors and patients with hyperuricemia and gouty arthritis. Conclusion.As a new approach in personalized diagnostics, a hyperuricemic (HU)-hemotest system was developed, which can serve as anin vitrocell model for studying the activation of inflammasome by inflammatory signaling molecules in gouty arthritis.